Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Osteoarthritis (OA) is a degenerative joint disease characterized by the breakdown of cartilage, leading to pain, stiffness, and reduced mobility. It accounts for around 528 million cases globally. There is a significant unmet clinical need for better therapies to treat osteoarthritis, as current treatments, such as pain relievers and anti-inflammatory drugs, only provide limited relief. Furthermore, the growing focus on disease-modifying osteoarthritis drugs (DMOADs) and regenerative therapeutics is likely to support pipeline growth in the coming years, offering hope for more effective treatment options.

  • Major companies involved in the osteoarthritis pipeline drugs market include Kolon TissueGene, Inc., Cytonics Corporation, and others.
  • Leading drugs currently in the pipeline include TG-C, LNA043, SAR446959, and others.
  • Advancements in disease-modifying treatments, increased emphasis on regenerative therapies, and a rising demand for effective solutions to address the high unmet clinical needs in osteoarthritis management are driving growth in the osteoarthritis drug pipeline.

Report Coverage

The Osteoarthritis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into osteoarthritis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for osteoarthritis. The osteoarthritis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The osteoarthritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with osteoarthritis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to osteoarthritis.

Osteoarthritis Drug Pipeline Outlook

Osteoarthritis is a chronic degenerative joint disease caused by cartilage breakdown and inflammation, leading to joint pain, stiffness, and reduced mobility. The osteoarthritis drug pipeline focuses on disease-modifying osteoarthritis drugs (DMOADs), anti-inflammatory agents, and regenerative therapies aimed at slowing disease progression, reducing pain, and improving joint function.

Osteoarthritis treatment aims to alleviate pain and improve function. Common approaches include pain relievers, anti-inflammatory medications, corticosteroid injections, and physical therapy. In severe cases, joint replacement surgery may be necessary. Recent advancements in biologics and regenerative treatments also show promise in addressing the root causes of osteoarthritis.

Osteoarthritis Epidemiology

The osteoarthritis (OA) drug pipeline is evolving to address the high global burden of the disease. Osteoarthritis affects approximately 528 million people globally, with over 50 million cases in the United States. In the United Kingdom, knee osteoarthritis impacts 5.4 million people, while India reports a prevalence of 22% to 39%. This growing incidence underscores the urgent need for advanced therapeutics in the pipeline.

Osteoarthritis – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of osteoarthritis drug candidates based on several segmentations, including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Small Molecules
  • Monoclonal antibodies
  • Gene Therapies
  • Cell-based Therapies
  • Peptide Therapeutics

By Route of Administration

  • Oral
  • Parenteral
  • Others

Osteoarthritis – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total osteoarthritis clinical trials.

Osteoarthritis – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the osteoarthritis pipeline analysis include small molecules, monoclonal antibodies, gene therapies, cell-based therapies, and peptide therapeutics. The osteoarthritis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for osteoarthritis.

Osteoarthritis Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the osteoarthritis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed osteoarthritis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in osteoarthritis clinical trials:

  • Kolon TissueGene, Inc.
  • Cytonics Corporation
  • Shin Poong Pharmaceutical Co., Ltd.
  • Grunenthal
  • Sanofi
  • Novartis Pharmaceuticals
  • VivaTech International, Inc.
  • Amzell
  • Pacira Pharmaceuticals, Inc.
  • Rion Inc.
  • Taiwan Bio Therapeutics Inc.
  • Kangstem Biotech Co., Ltd.
  • Anterogen Co., Ltd.
  • Eli Lilly and Company

Osteoarthritis – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for osteoarthritis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of osteoarthritis drug candidates.

Drug: TG-C

The Phase 3 study, sponsored by Kolon TissueGene, Inc., aims to evaluate the efficacy and safety of TG-C in subjects with Kellgren/Lawrence Grade 2 or 3 osteoarthritis of the knee. The study, a randomized, double-blind, placebo-controlled trial, is expected to be completed by March 2026 with approximately 531 participants. It will assess both symptomatic relief and disease-modifying effects of TG-C, administered via intra-articular injection.

Drug: LNA043 Dosing Regimen A

The study sponsored by Novartis Pharmaceuticals aims to examine the efficacy, safety, and tolerabili...

Drug: SAR446959

The drug SAR446959, sponsored by Sanofi, is currently undergoing a Phase 1 study to assess its safet...

*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*

Reasons to Buy This Report

The Osteoarthritis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for osteoarthritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into osteoarthritis collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Osteoarthritis – Pipeline Insight Report

  • Which companies/institutions are leading the osteoarthritis drug development?
  • What is the efficacy and safety profile of osteoarthritis pipeline drugs?
  • Which company is leading the osteoarthritis pipeline development activities?
  • What is the current osteoarthritis commercial assessment?
  • What are the opportunities and challenges present in the osteoarthritis drug pipeline landscape?
  • What is the efficacy and safety profile of osteoarthritis pipeline drugs?
  • Which company is conducting major trials for osteoarthritis drugs?
  • Which companies/institutions are involved in osteoarthritis collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in osteoarthritis?

Related Reports

Osteoarthritis Therapeutics Market

Global Clinical Trials Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Drug Pipeline by Clinical Trial Phase

  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

Route of Administration

  • Oral
  • Parenteral
  • Others

Drug Classes

  • Small Molecules
  • Monoclonal Antibodies
  • Gene Therapies
  • Cell-based Therapies
  • Peptide Therapeutics

Leading Sponsors Covered

  • Kolon TissueGene, Inc.
  • Cytonics Corporation
  • Shin Poong Pharmaceutical Co. Ltd.
  • Grunenthal
  • Sanofi
  • Novartis Pharmaceuticals
  • VivaTech International, Inc.
  • Amzell
  • Pacira Pharmaceuticals, Inc.
  • Rion Inc.
  • Taiwan Bio Therapeutics Inc.
  • Kangstem Biotech Co., Ltd.
  • Anterogen Co., Ltd.
  • Eli Lilly and Company

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

1,999

1,799

Single User License

10 % Off

USD

3,099

2,789

Five User License

15 % Off

USD

4,599

3,909

Corporate License

15 % Off

USD

5,999

5,099

Mini Report

One User

USD 1,999

USD 1,799

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 3,099

USD 2,789

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 4,599

USD 3,909

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 5,999

USD 5,099

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124